Abstract
Traveling through several time zones results in a constellation of symptoms known as jet lag. These include reduced alertness, daytime fatigue, loss of appetite, reduced cognitive skills, and disruption of the sleep/wake cycle. In susceptible air travel passengers, jet lag may exacerbate affective illness and result in psychiatric morbidity. Dysregulation of circadian rhythms and melatonin secretion represent the common underlying factor in jet lag and other circadian disorders. Recent studies have established the effectiveness of strategically timed administration of melatonin and appropriate timed exposure to environmental schedules including light in counteracting the dysregulation (chronobiologic actions). With the introduction of melatonergic agonists such as ramelteon and tasimelteon, which have both a stronger affinity for MT1 and MT2 melatonin receptors and a longer half-life, new therapeutic options now exist for treating the sleep disturbances associated with jet lag. The melatonin analogs are unique inasmuch as they can also enhance daytime alertness. The recently introduced melatonergic antidepressant agomelatine, which has established its supremacy over other antidepressants in having a significant chronobiologic activity, represents a good choice for treating depressive symptoms that are associated with jet lag.
Similar content being viewed by others
References
Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science. 1999;284:2177–2181.
Hastings MH, Best JD, Ebling FJ, et al. Entrainment of the circadian clock. Prog Brain Res. 1996;111:147–174.
Lewy AJ, Emens J, Sack RL, et al. Zeitgeber hierarchy in humans: resetting the circadian phase positions of blind people using melatonin. Chronobiol Int. 2003;20:837–852.
Zisapel N. Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. CNS Drugs. 2001;15:311–328.
Pandi-Perumal SR, Trakht I, Spence DW, et al. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nat Clin Pract Neurol. 2008;4:436–447.
Zee PC, Manthena P. The brain’s master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Med Rev. 2007;11:59–70.
Samuels C. Sleep, recovery, and performance: the new frontier in high-performance athletics. Phys Med Rehabil Clin N Am. 2009;20:149–159,ix.
Sack RL. Clinical practice. Jet lag. N Engl J Med. 2010;362:440–447.
Waterhouse J, Reilly T. Managing jet lag. Sleep Med Rev. 2009;13:247–248.
Arendt J, Marks V. Physiological changes underlying jet lag. Br Med J (Clin Res Ed). 1982;284:144–146.
Kyriacou CP, Hastings MH. Circadian clocks: genes, sleep, and cognition. Trends Cogn Sci. 2010; 14:259–267.
Arendt J. Managing jet lag: some of the problems and possible new solutions. Sleep Med Rev. 2009;13:249–256.
Auger RR, Morgenthaler TI. Jet 13. lag and other sleep disorders relevant to the traveler. Travel Med Infect Dis. 2009;7:60–68.
Reilly T, Atkinson G, Waterhouse J. Travel fatigue and jet-lag. J Sports Sci. 1997;15:365–369.
Nicholson AN. Intercontinental air travel: the cabin atmosphere and circadian realignment. Travel Med Infect Dis. 2009;7:57–59.
Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517–549.
Morin LP, Allen CN. The circadian visual system, 2005. Brain Res Brain Res Rev. 2006;51:1–60.
Kalsbeek A, Perreau-Lenz S, Buijs RM. A network of (autonomic) clock outputs. Chronobiol Int. 2006;23:201–215.
Aschoff J, Wever R. The circadian system of man. In: Aschoff J, ed. Handbook of Behavioral Neurobiology. Volume 4. Biological Rhythms. New York: Plenum Press; 1981:311–331.
Monk TH. Aging human circadian rhythms: conventional wisdom may not always be right. J Biol Rhythms. 2005;20:366–374.
Davidson AJ, Sellix MT, Daniel J, et al. Chronic jet-lag increases mortality in aged mice. Curr Biol. 2006;16:R914–R916.
Tresguerres J, Ariznavarreta C, Granados B, et al. Circadian urinary 6-sulphatoxymelatonin, cortisol excretion and locomotor activity in airline pilots during transmeridian flights. J Pineal Res. 2001;31:16–22.
Ariznavarreta C, Cardinali DP, Villanua M, et al. Circadian rhythms in airline pilots submitted to long-haul transmeridian flights. Aviat Space Environ Med. 2002;73:445–455.
Shanahan TL, Czeisler CA. Physiological effects of light on the human circadian pacemaker. Semin Perinatol. 2000;24:299–320.
Takahashi T, Sasaki M, Itoh H, et al. Melatonin alleviates jet lag symptoms caused by an 11.hour eastward flight. Psychiatry Clin Neurosci. 2002;56:301–302.
Nicholson AN. Sleep and intercontinental flights. Travel Med Infect Dis. 2006;4:336–339.
Roehrs T, Turner L, Roth T. Effects of sleep loss on waking actigraphy. Sleep. 2000;23:793–797.
Wegmann HM, Gundel A, Naumann M, et al. Sleep, sleepiness, and circadian rhythmicity in aircrews operating on transatlantic routes. Aviat Space Environ Med. 1986;57:B53–B64.
Samel A, Wegmann HM, Vejvoda M. Jet lag and sleepiness in aircrew. J Sleep Res. 1995;4:30–36.
Beaumont M, Batejat D, Pierard C, et al. Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. J Appl Physiol. 2004;96:50–58.
Sack RL. The pathophysiology of jet lag. Travel Med Infect Dis. 2009;7:102–110.
Costa G, Haus E, Stevens R. Shift work and cancer — considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health. 2010;36:163–179.
Stevens RG, Blask DE, Brainard GC, et al. Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. Environ Health Perspect. 2007;115:1357–1362.
Arendt J. Shift work: coping with the biological clock. Occup Med (Lond). 2010;60:10–20.
Grundy A, Sanchez M, Richardson H, et al. Light intensity exposure, sleep duration, physical activity, and biomarkers of melatonin among rotating shift nurses. Chronobiol Int. 2009;26:1443–1461.
Thorpy MJ. Managing the patient with shift-work disorder. J Fam Pract. 2010;59:S24–S31.
Lemmer B, Kern RI, Nold G, et al. Jet lag in athletes after eastward and westward time-zone transition. Chronobiol Int. 2002;19:743–764.
Steenland K, Deddens JA. Effect of travel and rest on performance of professional basketball players. Sleep. 1997;20:366–369.
Schwartz JR. Pharmacologic management of daytime sleepiness. J Clin Psychiatry. 2004;65Suppl 16:46–49.
Caldwell JA. Fatigue in aviation. Travel Med Infect Dis. 2005;3:85–96.
Pandi-Perumal SR, Srinivasan V, Maestroni GJM, et al. Melatonin: nature’s most versatile biological signal? FEBS Lett. 2006;273:2813–2838.
Srinivasan V, Pandi-Perumal SR, Spence DW, et al. Potential use of melatonergic drugs in analgesia: mechanisms of action. Brain Res Bull. 2010;81:362–371.
Srinivasan V, Pandi-Perumal SR, Spence DW, et al. Melatonin in septic shock: some recent concepts. J Crit Care. In press.
Lewy AJ, Emens J, Jackman A, et al. Circadian uses of melatonin in humans. Chronobiol Int. 2006;23:403–412.
Dawson D, Armstrong SM. Chronobiotics — drugs that shift rhythms. Pharmacol Ther. 1996;69:15–36X.
Bartness TJ, Goldman BD. Mammalian pineal melatonin: a clock for all seasons. Experientia. 1989;45:939–945.
Brown GM, Pandi-Perumal SR, Trakht I, et al. Melatonin and its relevance to jet lag. Travel Med Infect Dis. 2009;7:69–81.
Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24.
Brown GM, Pandi-Perumal SR, Trakht I, et al. The role of melatonin in seasonal affective disorder.In: Partonen T and Pandi-Perumal SR, eds. Seasonal Affective Disorder Practice and Research. 2nd ed. Oxford: Oxford University Press; 2010:149–162.
Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther. 1995;57:552–558.
Dollins AB, Zhdanova IV, Wurtman RJ, et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A. 1994;91:1824–1828.
Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005;9:25–39.
Burgess HJ, Sharkey KM, Eastman CI. Bright light, dark and melatonin can promote circadian adaptation in night shift workers. Sleep Med Rev. 2002;6:407–420.
Dubocovich ML, Delagrange P, Krause DN, et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Nomenclature, classification and pharmacology of G proteincoupled melatonin receptors. Phamacol Rev. In press.
Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27:101–110.
Liu C, Weaver DR, Jin X, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19:91–102.
von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002;309:151–162.
Hunt AE, Al Ghoul WM, Gillette MU, et al. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol. 2001;280:C110–C118.
Wan Q, Man HY, Liu F, et al. Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat Neurosci. 1999;2:401–403.
Liu C, Reppert SM. GABA synchronizes clock cells within the suprachiasmatic circadian clock. Neuron. 2000;25:123–128.
Gherardin T. Jet lag. A problem for ‘long haul’ travellers. Aust Fam Physician. 1999;28:833.
Arendt J. Jet-lag. Lancet. 1998;351:293–294.
Kennaway DJ, Wright H. Melatonin and circadian rhythms. Curr Top Med Chem. 2002;2:199–209.
Paul MA, Miller JC, Gray GW, et al. Melatonin treatment for eastward and westward travel preparation. Psychopharmacology (Berl). 2010;208:377–386.
Cardinali DP, Bortman GP, Liotta G, et al. A multifactorial approach employing melatonin to accelerate resynchronization of sleep-wake cycle after a 12 time-zone westerly transmeridian flight in elite soccer athletes. J Pineal Res. 2002;32:41–46.
Arendt J, Aldhous M, Marks V. Alleviation of jet lag by melatonin: preliminary results of controlled double blind trial. Br Med J (Clin Res Ed). 1986;292:1170.
Petrie K, Dawson AG, Thompson L, et al. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol Psychiatry. 1993;33:526–530.
Claustrat B, Brun J, David M, et al. Melatonin and jet lag: confirmatory result using a simplified protocol. Biol Psychiatry. 1992;32:705–711.
Lino A, Silvy S, Condorelli L, et al. Melatonin and jet lag: treatment schedule. Biol Psychiatry. 1993;34:587.
Spitzer RL, Terman M, Williams JB, et al. Jet lag: clinical features, validation of a new syndromespecific scale, and lack of response to melatonin in a randomized, double-blind trial. Am J Psychiatry. 1999;156:1392–1396.
Samel A. Melatonin and jet-lag. Eur J Med Res. 1999;4:385–388.
Edwards BJ, Atkinson G, Waterhouse J, et al. Use of melatonin in recovery from jet-lag following an eastward flight across 10 time-zones. Ergonomics. 2000;43:1501–1513.
Revell VL, Burgess HJ, Gazda CJ, et al. Advancing human circadian rhythms with afternoon melatonin and morning intermittent bright light. J Clin Endocrinol Metab. 2006;91:54–59.
Arendt J, Aldhous M. Further evaluation of the treatment of jet-lag by melatonin: a double-blind crossover study. Annu Rev Chronopharmacol. 1986;5:53–55.
Petrie K, Conaglen JV, Thompson L, et al. Effect of melatonin on jet lag after long haul flights. BMJ. 1989;298:705–707.
Nickelsen I, Lang A, Bergau I. The effect of 6, 9, and 11-hour time shifts on circadian rhythms: adaptation of sleep parameters and hormonal patterns following the intake of melatonin or placebo. Adv Pineal Res. 1991;5:303–306.
Comperatore CA, Lieberman HR, Kirby AW, et al. Melatonin efficacy in aviation missions requiring rapid deployment and night operations. Aviat Space Environ Med. 1996;67:520–524.
Suhner A, Schlagenhauf P, Johnson R, et al. Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. Chronobiol Int. 1998;15:655–666.
Suhner A, Schlagenhauf P, Hofer I, et al. Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. Aviat Space Environ Med. 2001;72:638–646.
Pierard C, Beaumont M, Enslen M, et al. Resynchronization of hormonal rhythms after an eastbound flight in humans: effects of slow-release caffeine and melatonin. Eur J Appl Physiol. 2001;85:144–150.
Paul MA, Gray G, Sardana TM, et al. Melatonin and zopiclone as facilitators of early circadian sleep in operational air transport crews. Aviat Space Environ Med. 2004;75:439–443.
Cardinali DP, Furio AM, Reyes MP, et al. The use of chronobiotics in the resynchronization of the sleep/wake cycle. Cancer Causes Control. 2006;17:601–609.
Arendt J, Skene DJ, Middleton B, et al. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J Biol Rhythms. 1997;12:604–617.
Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002;(2):CD001520.
Czeisler CA, Kronauer RE, Allan JS, et al. Bright light induction of strong (type 0) resetting of the human circadian pacemaker. Science. 1989;244:1328–1333.
Paul MA, Miller JC, Love RJ, et al. Timing light treatment for eastward and westward travel preparation. Chronobiol Int. 2009;26:867–890.
Berson DM. Phototransduction in ganglion-cell photoreceptors. Pflugers Arch. 2007;454:849–855.
Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review. Sleep. 2007;30:1460–1483.
Bellon A. Searching for new options for treating insomnia: are melatonin and ramelteon beneficial? J Psychiatr Pract. 2006;12:229–243.
Dobkin RD, Menza M, Bienfait KL, et al. Ramelteon for the treatment of insomnia in menopausal women. Menopause Int. 2009;15:13–18.
Gross PK, Nourse R, Wasser TE. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. J Clin Sleep Med. 2009;5:28–33.
Hirai K, Kita M, Ohta H, et al. Ramelteon (TAK- 375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms. 2005;20:27–37.
Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48:301–310.
Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7:17–24.
Roth T, Seiden D, Wang-Weigand S, et al. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007;23:1005–1014.
Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3:495–504.
Mini L, Wang-Weigand S, Zhang J. Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect. Clin Ther. 2008;30:1316–1323.
Richardson GS, Zee PC, Wang-Weigand S, et al. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med. 2008;4:456–461.
Zee PC, Wang-Weigand S, Wright KP Jr., et al. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Sleep Med. 2010;11:525–533.
Minors DS, Waterhouse JM, Wirz-Justice A. A human phase-response curve to light. Neurosci Lett. 1991;133:36–40.
Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009;373:482–491.
Jauhar P, Weller MP. Psychiatric morbidity and time zone changes: a study of patients from Heathrow airport. Br J Psychiatry. 1982;140:231–235.
Young DM. Psychiatric morbidity in travelers to Honolulu, Hawaii. Compr Psychiatry. 1995;36:224–228.
Katz G, Knobler HY, Laibel Z, et al. Time zone change and major psychiatric morbidity: the results of a 6-year study in Jerusalem. Compr Psychiatry. 2002;43:37–40.
Srinivasan V, Spence DW, Pandi-Perumal SR, et al. Jet lag: therapeutic use of melatonin and possible application of melatonin analogues. Travel Med Infect Dis. 2008;6:17–28.
Halberg F, Vestergaard P, Sakai M. Rhythmometry on urinary 17-ketosteroid excretion by healthy men and women and patients with chronic schizophrenia; possible chronopathology in depressive illness. Arch Anat Histol Embryol. 1968;51:299–311.
Wehr TA, Wirz-Justice A. Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria. 1982;15:31–39.
Healy D, Waterhouse JM. The circadian system and the therapeutics of the affective disorders. Pharmacol Ther. 1995;65:241–263.
Lustberg L, Reynolds CF. Depression and insomnia: questions of cause and effect. Sleep Med Rev. 2000;4:253–262.
Reynolds CF, III, Monk TH, Hoch CC, et al. Electroencephalographic sleep in the healthy “old old”: a comparison with the “young old” in visually scored and automated measures. J Gerontol. 1991;46:M39–M46.
Bunney JN, Potkin SG. Circadian abnormalities, molecular clock genes and chronobiological treatments in depression. Br Med Bull. 2008;86:23–32.
Quera-Salva MA, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol. 2010;25:222–229.
Riemann D, Berger M, Voderholzer U. Sleep and depression — results from psychobiological studies: an overview. Biol Psychol. 2001;57:67–103.
Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol. 2006;21(suppl. 1):S25–S29.
Moltzen EK, Bang-Andersen B. Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century — a medicinal chemistry survey. Curr Top Med Chem. 2006;6:1801–1823.
Yous S, Andrieux J, Howell HE, et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem. 1992;35:1484–1486.
Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306:954–964.
Loo H, Hale A, D’haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239–247.
Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16:93–100.
Montgomery SA. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur Neuropsychopharmacol. 2006;16(suppl. 5):S633–S638.
Kupfer DJ. Depression and associated sleep disturbances: patient benefits with agomelatine. Eur Neuropsychopharmacol. 2006;16(suppl. 5):S639–S643.
Srinivasan V, Smits M, Spence W, et al. Melatonin in mood disorders. 2006;7:138–151.
Branchey L, Weinberg U, Branchey M, et al. Simultaneous study of 24-hour patterns of melatonin and cortisol secretion in depressed patients. Neuropsychobiology. 1982;8:225–232.
Claustrat B, Chazot G, Brun J, et al. A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biol Psychiatry. 1984;19:1215–1228.
Nair NP, Hariharasubramanian N, Pilapil C. Circadian rhythm of plasma melatonin in endogenous depression. Prog Neuropsychopharmacol Biol Psychiatry. 1984;8:715–718.
Beck-Friis J, Kjellman BF, Aperia B, et al. Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome. Acta Psychiatr Scand. 1985;71:319–330.
Wehr TA, Sack DA, Rosenthal NE. Antidepressant effects of sleep deprivation and phototherapy. Acta Psychiatr Belg. 1985;85:593–602.
Rubin RT, Heist EK, McGeoy SS, et al. Neuroendocrine aspects of primary endogenous depression. XI. Serum melatonin measures in patients and matched control subjects. Arch Gen Psychiatry. 1992;49:558–567.
Sekula LK, Lucke JF, Heist EK, et al. Neuroendocrine aspects of primary endogenous depression. XV: mathematical modeling of nocturnal melatonin secretion in major depressives and normal controls. Psychiatry Res. 1997;69:143–153.
Crasson M, Kjiri S, Colin A, et al. Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology. 2004;29:1–12.
Tuunainen A, Kripke DF, Elliott JA, et al. Depression and endogenous melatonin in postmenopausal women. J Affect Disord. 2002;69:149–158.
Hardeland R, Poeggeler B, Srinivasan V, et al. Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58:1–10.
Leproult R, Van Onderbergen A, L’hermite-Baleriaux M, et al. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf). 2005;63:298–304.
Pjrek E, Winkler D, Konstantinidis A, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl). 2007;190:575–579.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Srinivasan, V., Singh, J., Pandi-Perumal, S.R. et al. Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. Adv Therapy 27, 796–813 (2010). https://doi.org/10.1007/s12325-010-0065-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-010-0065-y